IMPORTANT SAFETY INFORMATIONU.S. FULL PRESCRIBING INFORMATION, including Boxed WARNING and Medication Guide

SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable. SAFETY INFORMATION CONTINUED BELOW

Samsca

Prevalence and Prognosis of Hyponatremia

About Hyponatremia Prevalence and Prognosis Etiology and Pathogenesis Role of Vasopressin in Hyponatremia Hypervolemic Hyponatremia Pathophysiology of Hyponatremia in Heart Failure Pathophysiology of Hyponatremia in Cirrhosis Euvolemic Hyponatremia Pathophysiology of SIADH in Hyponatremia Management of Hyponatremia Acute vs Chronic Hyponatremia The Role of Vasopressin Receptor Antagonists

Kirk—hyponatremia signs and symptoms video

Presenting Signs and Symptoms of Hyponatremia
J. Douglas Kirk, MD

Amin—hyponatremia incidence and signs video

Incidence and Signs of Hyponatremia
Alpesh Amin, MD

High prevalence in healthcare institutions

Hyponatremia is a significant clinical disorder that may have serious consequences. The prevalence of hyponatremia in the United States is estimated to range from 3.16 million to 6.07 million patients.¹

Who is at risk in the hospital?

Hyponatremia affects a variety of patient types in the hospital

Hyponatremia patient types

Patients with heart failure
16% of patients with heart failure (HF) develop hyponatremia³
Patients with advanced disease are at further risk as a result of excess sodium and water retention promoted by increased vasopressin levels and compromised glomerular filtration^5-7
Patients with cirrhosis
35% of patients with cirrhosis develop hyponatremia⁸
Patients with advanced chronic disease are particularly prone⁷
Patients With Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
Accounts for the majority of all euvolemic hyponatremia^8,10

Prevalence in the hospital and community

Risk factors for hyponatremia^8,9

In addition to the important comorbidities discussed, certain medical conditions and medications have the potential to increase the risk of hyponatremia.^8,9 Some may be a selected condition such as surgery, age or renal dysfunction. Others may be by selected drug class including diuretics, antipsychotics and tricyclic antidepressants.^8,9

Signs and symptoms

Patients who experience hyponatremia may exhibit clinical manifestations that are largely related to central nervous system dysfunction.¹⁰

It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients.

Click the following links to explore the site further:

References:

Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc. 2006;4:10.
Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med. 2007;167(18):1998-2005.
Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clin J Med. 2006;73(suppl 3):S4-S12.
Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am J Cardiol. 2005;95(suppl):14B-23B.
Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(suppl 11A):S1-S21.
Angeli P, Wong F, Watson H, Ginès P, CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44(6):1535-1542.
Kumar S, Berl T. Sodium. Lancet. 1998;352(9123):220-228.
Adrogué HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol. 2005;25(3):240-249.
Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144-153.
Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342(21):1581-1589.

INDICATION

SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

Important Limitations

Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA.
It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients

IMPORTANT SAFETY INFORMATION

SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too-rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.

SAMSCA is contraindicated in the following conditions:

— Urgent need to raise serum sodium acutely
— Inability of the patient to sense or appropriately respond to thirst
— Hypovolemic hyponatremia
— Concomitant use of strong CYP 3A inhibitors
— Anuric patients

Too-Rapid Correction of Serum Sodium Can Cause Serious Neurologic Sequelae – During initiation and after titration monitor patients to assess serum sodium concentrations and neurologic status. Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of serum sodium. In patients receiving SAMSCA who develop too rapid a rise in serum sodium, discontinue or interrupt treatment with SAMSCA and consider administration of hypotonic fluid. Fluid restriction during the first 24 hours with SAMSCA may increase the likelihood of overly-rapid correction of serum sodium, and should generally be avoided.
Gastrointestinal Bleeding in Patients With Cirrhosis – Use in cirrhotic patients only when need to treat outweighs this risk
Dehydration and Hypovolemia – In patients who develop medically significant signs or symptoms of hypovolemia, discontinuation is recommended. Dehydration and hypovolemia can occur, especially in potentially volume-depleted patients receiving diuretics or those who are fluid restricted
Co-administration With Hypertonic Saline – Not recommended
Other Drugs Affecting Exposure to SAMSCA

— CYP 3A Inhibitors – Do not use with strong inhibitors of CYP 3A; avoid concomitant use with moderate CYP 3A inhibitors
— CYP 3A Inducers – Avoid concomitant use with CYP 3A inducers. If co-administered, the dose of SAMSCA may need to be increased
— P-gp Inhibitors – The dose of SAMSCA may have to be reduced if co-administered with P-gp inhibitors

Hyperkalemia or Drugs that Increase Serum Potassium – Monitor serum potassium levels in patients with a serum potassium >5 mEq/L and in patients receiving drugs known to increase serum potassium levels

Pregnancy and Nursing Mothers – SAMSCA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because many drugs are excreted into human milk and because of the potential for serious adverse reactions in nursing infants from SAMSCA, a decision should be made to discontinue nursing or SAMSCA, taking into consideration the importance of SAMSCA to the mother.

Commonly observed adverse reactions – (SAMSCA incidence ≥5% more than placebo, respectively): thirst (16% vs 5%), dry mouth (13% vs 4%), asthenia (9% vs 4%), constipation (7% vs 2%), pollakiuria or polyuria (11% vs 3%) and hyperglycemia (6% vs 1%).

Please see U.S. FULL PRESCRIBING INFORMATION, including Boxed WARNING, and Medication Guide.

Manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan.
Distributed and marketed by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850.
SAMSCA is a registered trademark of Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan.

Tell a Colleague

You are now leaving www.samsca.com

Prevalence and Prognosis of Hyponatremia

High prevalence in healthcare institutions

Who is at risk in the hospital?

Hyponatremia affects a variety of patient types in the hospital

Risk factors for hyponatremia^8,9

Signs and symptoms

It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients.

Click the following links to explore the site further:

References:

INDICATION

Important Limitations

IMPORTANT SAFETY INFORMATION

SAMSCA is contraindicated in the following conditions:

Tell a Colleague

You are now leaving www.samsca.com

Prevalence and Prognosis of Hyponatremia

High prevalence in healthcare institutions

Who is at risk in the hospital?

Hyponatremia affects a variety of patient types in the hospital

Risk factors for hyponatremia8,9

Signs and symptoms

It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients.

Click the following links to explore the site further:

References:

INDICATION

Important Limitations

IMPORTANT SAFETY INFORMATION

SAMSCA is contraindicated in the following conditions:

Risk factors for hyponatremia^8,9